{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.60","upperLimit":"14.18","value":"5.8"}]}],"title":"Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.36","upperLimit":"15.89","value":"7.1"}]}],"title":"Week 60"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.58","upperLimit":"13.99","value":"5.7"}]}],"title":"Week 72"}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"Percentage of patients achieving IGF-1 \\<ULN at weeks 48, 60 \\& 72 for participants with up-titrated to Pasireotide LAR 60 mg mg","dispersionType":"95% Confidence Interval","groups":[{"description":"This is the subset of participants in the FAS who started treatment with 40 mg pasireotide LAR in the core phase and were up-titrated to pasireotide LAR 60 mg.","id":"OG000","title":"Up-titrated to Pasireotide LAR 60 mg"}],"paramType":"NUMBER","populationDescription":"Extension Full Analysis Set (Extension FAS) included all the patients who received at least one dose of pasireotide LAR in the extension phase.","reportingStatus":"POSTED","timeFrame":"Weeks 48, 60 & 72","title":"Extension Phase: Percentage of Participants With Mean GH < 1 μg/L and IGF-1 < ULN at Weeks 48, 60 & 72 (Up-titrated to Pasireotide LAR 60 mg)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}